Asteroseismology of Eclipsing Binary Stars in the Kepler Era

Eclipsing binary stars have long served as benchmark systems to measure fundamental stellar properties. In the past few decades, asteroseismology - the study of stellar pulsations - has emerged as a new powerful tool to study the structure and evolution of stars across the HR diagram. Pulsating stars in eclipsing binary systems are particularly valuable since fundamental properties (such as radii and masses) can determined using two independent techniques. Furthermore, independently measured properties from binary orbits can be used to improve asteroseismic modeling for pulsating stars in which mode identifications are not straightforward. This contribution provides a review of asteroseismic detections in eclipsing binary stars, with a focus on space-based missions such as CoRoT and Kepler, and empirical tests of asteroseismic scaling relations for stochastic ("solar-like") oscillations.Comment: 28 pages, 12 figures, 2 tables; Proceedings of the AAS topical conference "Giants of Eclipse" (AASTCS-3), July 28 - August 2 2013, Monterey, C

Kepler-22b: A 2.4 Earth-radius Planet in the Habitable Zone of a Sun-like Star

A search of the time-series photometry from NASA's Kepler spacecraft reveals a transiting planet candidate orbiting the 11th magnitude G5 dwarf KIC 10593626 with a period of 290 days. The characteristics of the host star are well constrained by high-resolution spectroscopy combined with an asteroseismic analysis of the Kepler photometry, leading to an estimated mass and radius of 0.970 +/- 0.060 MSun and 0.979 +/- 0.020 RSun. The depth of 492 +/- 10ppm for the three observed transits yields a radius of 2.38 +/- 0.13 REarth for the planet. The system passes a battery of tests for false positives, including reconnaissance spectroscopy, high-resolution imaging, and centroid motion. A full BLENDER analysis provides further validation of the planet interpretation by showing that contamination of the target by an eclipsing system would rarely mimic the observed shape of the transits. The final validation of the planet is provided by 16 radial velocities obtained with HIRES on Keck 1 over a one year span. Although the velocities do not lead to a reliable orbit and mass determination, they are able to constrain the mass to a 3{\sigma} upper limit of 124 MEarth, safely in the regime of planetary masses, thus earning the designation Kepler-22b. The radiative equilibrium temperature is 262K for a planet in Kepler-22b's orbit. Although there is no evidence that Kepler-22b is a rocky planet, it is the first confirmed planet with a measured radius to orbit in the Habitable Zone of any star other than the Sun.Comment: Accepted to Ap

KOI-3158: The oldest known system of terrestrial-size planets

The first discoveries of exoplanets around Sun-like stars have fueled efforts to find ever smaller worlds evocative of Earth and other terrestrial planets in the Solar System. While gas-giant planets appear to form preferentially around metal-rich stars, small planets (with radii less than four Earth radii) can form under a wide range of metallicities. This implies that small, including Earth-size, planets may have readily formed at earlier epochs in the Universe's history when metals were far less abundant. We report Kepler spacecraft observations of KOI-3158, a metal-poor Sun-like star from the old population of the Galactic thick disk, which hosts five planets with sizes between Mercury and Venus. We used asteroseismology to directly measure a precise age of 11.2 ± 1.0 Gyr for the host star, indicating that KOI-3158 formed when the Universe was less than 20 % of its current age and making it the oldest known system of terrestrial-size planets. We thus show that Earth-size planets have formed throughout most of the Universe's 13.8-billion-year history, providing scope for the existence of ancient life in the Galaxy

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

BACKGROUND: Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when SARS-CoV-2 vaccination was introduced. METHODS: In this follow up study, plasma and nasosorption samples were prospectively collected from 446 adults hospitalised for COVID-19 between February 2020 and March 2021 via the ISARIC4C and PHOSP-COVID consortia. IgA and IgG responses to NP and S of ancestral SARS-CoV-2, Delta and Omicron (BA.1) variants were measured by electrochemiluminescence and compared with plasma neutralisation data. FINDINGS: Strong and consistent nasal anti-NP and anti-S IgA responses were demonstrated, which remained elevated for nine months (p < 0.0001). Nasal and plasma anti-S IgG remained elevated for at least 12 months (p < 0.0001) with plasma neutralising titres that were raised against all variants compared to controls (p < 0.0001). Of 323 with complete data, 307 were vaccinated between 6 and 12 months; coinciding with rises in nasal and plasma IgA and IgG anti-S titres for all SARS-CoV-2 variants, although the change in nasal IgA was minimal (1.46-fold change after 10 months, p = 0.011) and the median remained below the positive threshold determined by pre-pandemic controls. Samples 12 months after admission showed no association between nasal IgA and plasma IgG anti-S responses (R = 0.05, p = 0.18), indicating that nasal IgA responses are distinct from those in plasma and minimally boosted by vaccination. INTERPRETATION: The decline in nasal IgA responses 9 months after infection and minimal impact of subsequent vaccination may explain the lack of long-lasting nasal defence against reinfection and the limited effects of vaccination on transmission. These findings highlight the need to develop vaccines that enhance nasal immunity. FUNDING: This study has been supported by ISARIC4C and PHOSP-COVID consortia. ISARIC4C is supported by grants from the National Institute for Health and Care Research and the Medical Research Council. Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research. The PHOSP-COVD study is jointly funded by UK Research and Innovation and National Institute of Health and Care Research. The funders were not involved in the study design, interpretation of data or the writing of this manuscript